216 related articles for article (PubMed ID: 29479992)
1. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
2. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
[TBL] [Abstract][Full Text] [Related]
3. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.
Morris TA; DeCastro CM; Diehl LF; Gockerman JP; Lagoo AS; Li Z; Moore JO; Rizzieri DA; Rao AV
Leuk Res; 2013 Jan; 37(1):28-31. PubMed ID: 23046833
[TBL] [Abstract][Full Text] [Related]
4. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
6. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
7. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
8. Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study.
Tedjaseputra A; Roy S; Htun K; Oh D; McQuilten Z; Yeh P; Bennett A; Low MSY; Chunilal S; Wood EM; Shortt J
Pathology; 2024 Jun; 56(4):548-555. PubMed ID: 38580614
[TBL] [Abstract][Full Text] [Related]
9. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y; Leiba R; Ganzel C; Saban R; Gatt M; Ram R; Arad A; Bulvik S; Hellmann I; Gino-Moor S; Zuckerman T; Hoffman R; Horowitz N; Lavi N; Ringelstein S; Henig I; Hayun M; Rowe JM
Am J Hematol; 2015 Dec; 90(12):1159-64. PubMed ID: 26435038
[TBL] [Abstract][Full Text] [Related]
11. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.
England JT; Saini L; Hogge D; Forrest D; Narayanan S; Power M; Nevill T; Kuchenbauer F; Hudoba M; Szkotak A; Brandwein J; Sanford D
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e427-e436. PubMed ID: 32201130
[TBL] [Abstract][Full Text] [Related]
12. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
13. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
[TBL] [Abstract][Full Text] [Related]
15. Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia.
Archimbaud E; Treille-Ritouet D; Guyotat D; Viala JJ; Fiere D
Leuk Res; 1987; 11(3):281-3. PubMed ID: 3470576
[TBL] [Abstract][Full Text] [Related]
16. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
19. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
20. CD34 immunohistochemistry in bone marrow biopsies for early response assessment in acute myeloid leukemia.
Jain S; Mahapatra M; Pati HP
Int J Lab Hematol; 2015 Dec; 37(6):746-51. PubMed ID: 26248894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
